Eli Lilly is set for another win in the glucagon-like peptide-1 (GLP-1) sector as its triple-g agonist, retatrutide, has succeeded in type 2 diabetes and obesity. Marking the four ...

The funds will help Crystalys progress its clinical-stage development efforts and commercialisation plans for its gout drug, dotinurad.

Devonian Health Group has received authorisation from Health Canada for its CTA to begin a Phase II/III study of Thykamine cream to treat mild-to-moderate atopic dermatitis in paediatric patients.

The Phase III trial failed to meet its co-primary endpoints or any of its key secondary endpoints. Credit: Ton Photographer 4289 / Shuttertock.com Kolon TissueGene’s stock has dropped after a Phase ...

Trellis Bioscience has closed a $9m Series C round to support the completion of its ongoing Phase II trial evaluating calpurbatug for chronic PJI.

GSK will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.

Following a turbulent funding environment, biotechs are seeking to generate more data earlier to reassure investors.

When the FDA approved Madrigal's Rezdiffra in 2024, it was the first marketed drug ever for MASH, which affects millions of American adults.

Biogen said that the 60mg cohort saw greater benefit than either of the115mg cohorts. Credit: Tada Images / Shutterstock.com Biogen’s stock has dropped after it released mixed data on its ...

Ipsen claims that Dysport has become the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.

Arrowhead's EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve.

The M72/AS01E vaccine is an adjuvanted recombinant protein vaccine. Image Credit: art4stock / Shutterstock. The Bill & Melinda Gates Medical Research Institute (Gates MRI) has dosed the first patient ...